Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of investigational MenB + MenACWY combination vaccine formulations in adolescents and young adults
2010-023523-23Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group A, B, C, W and Y vaccine, meningococcal group B vaccine and meningococcal A conjugate vaccine in meningococcal disease (4 arms), sponsored by Novartis. Primary endpoint: Immunologic non-inferiority against meningococcal serogroups A, C, W-135, and Y. Started May 2011; status: completed.
02
Drugs
meningococcal group A, B, C, W and Y vaccinemeningococcal group B vaccinemeningococcal A conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2010-023523-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023523-23.